Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone ...

QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial ...

Announced Positive Clinical Data for Adult and Pediatric Netherton Patients ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- ...

Zeit Aktuelle Nachrichten 14:06 Quoin Pharmaceuticals regains Nasdaq compliance 13:46 Quoin Pharmaceuticals erfüllt wieder NASDAQ-Mindestangebotspreisanforderung 13: ...

Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling ...

A 54-year-old woman with an 8-year history of recurrent palmoplantar pustulosis, a 6-year history of sternoclavicular joint pain, and a 2-year history of eye discomfort and swelling was admitted to ...